Investment case
Scholar Rock Holding Corporation
SRRK · 8 developments mapped · last assessed 2026-09-14
Market Ontology has mapped 8 macro, policy, and market developments to Scholar Rock Holding Corporation since 2026-09-12. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for SRRK yet, so no modelled value is shown. The SRRK valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run SRRK on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
Direct commercialization of a novel therapeutic, market entry into a high-value rare disease segment.
· Moves peak sales estimates for isembyld, probability of success for pipeline assets (de risking), cost of goods sold for isembyld
What changed, by assumption
- 2026-09-14FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
- 2026-09-12FDA Approves Isembyld for Spinal Muscular Atrophy
- 2026-09-12FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy
- 2026-09-14FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA
- 2026-09-13FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
- 2026-09-12FDA approves Scholar Rock's Isembyld for spinal muscular atrophy
- 2026-09-13FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted SMA Therapy
- 2026-09-12FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-06 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-08-06 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-14 | FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy | Bullish | 1-3m | 0.90 |
| 2026-09-14 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA | Bullish | 1-3m | 0.90 |
| 2026-09-13 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted SMA Therapy | Bullish | 1-3m | 0.90 |
| 2026-09-13 | FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy | Bullish | 1-3m | 0.90 |
| 2026-09-12 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA | Bullish | 1-3m | 0.90 |
| 2026-09-12 | FDA Approves Isembyld for Spinal Muscular Atrophy | Bullish | 1-3m | 0.90 |
| 2026-09-12 | FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy | Bullish | 1-5y | 0.90 |
| 2026-09-12 | FDA approves Scholar Rock's Isembyld for spinal muscular atrophy | Bullish | 1-3m | 0.90 |